Transglutaminases: The missing link in nephrogenic systemic fibrosis

Amy C. Parsons, Gil Yosipovitch, Daniel J. Sheehan, Omar P. Sangüeza, Charles S. Greenberg, David C. Sane

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Nephrogenic systemic fibrosis (NSF), also known as nephrogenic fibrosing dermopathy (NFD), occurs in renal failure patients after gadolinium contrast exposure. The fibrosis of the dermis and subcutaneous septae accompanies fibrosis of other organs, including the heart, liver, lungs, and muscle. The fibrotic skin demonstrates increased dermal collagen, fibroblasts, and mucin. The mechanism by which gadolinium is associated with fibrosis is not known.We tested the hypothesis that upregulation of transglutaminases contributes to the fibrosis seen in the organs, including skin, of renal failure patients exposed to gadolinium contrast.We performed immunohistochemical studies using antibodies to transglutaminase-2, factor XIIIa, transglutaminase isopeptide, and the histiocyte marker CD68 on five archived skin biopsies of NSF. The results indicate that the dermal fibroblasts and histiocytes of NSF express transglutaminase-2, CD68, factor XIIIa, and transglutaminase isopeptide, indicating increased expression and/or activation of transglutaminases in NSF. We recommend further research into the use of transglutaminase inhibitors in the treatment and prevention of NSF.

Original languageEnglish (US)
Pages (from-to)433-436
Number of pages4
JournalAmerican Journal of Dermatopathology
Volume29
Issue number5
DOIs
StatePublished - Oct 1 2007
Externally publishedYes

Fingerprint

Nephrogenic Fibrosing Dermopathy
Transglutaminases
Gadolinium
Fibrosis
Skin
Factor XIIIa
Histiocytes
Renal Insufficiency
Fibroblasts
Mucins
Dermis
Up-Regulation
Collagen
Biopsy
Muscles
Lung
Antibodies
Liver
Research

Keywords

  • Gadolinium
  • Nephrogenic fibrosing dermopathy
  • Nephrogenic systemic fibrosis
  • Renal failure
  • Transglutaminase

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Dermatology

Cite this

Parsons, A. C., Yosipovitch, G., Sheehan, D. J., Sangüeza, O. P., Greenberg, C. S., & Sane, D. C. (2007). Transglutaminases: The missing link in nephrogenic systemic fibrosis. American Journal of Dermatopathology, 29(5), 433-436. https://doi.org/10.1097/DAD.0b013e318156e43f

Transglutaminases : The missing link in nephrogenic systemic fibrosis. / Parsons, Amy C.; Yosipovitch, Gil; Sheehan, Daniel J.; Sangüeza, Omar P.; Greenberg, Charles S.; Sane, David C.

In: American Journal of Dermatopathology, Vol. 29, No. 5, 01.10.2007, p. 433-436.

Research output: Contribution to journalArticle

Parsons, Amy C. ; Yosipovitch, Gil ; Sheehan, Daniel J. ; Sangüeza, Omar P. ; Greenberg, Charles S. ; Sane, David C. / Transglutaminases : The missing link in nephrogenic systemic fibrosis. In: American Journal of Dermatopathology. 2007 ; Vol. 29, No. 5. pp. 433-436.
@article{791e74f44f5941ecb4449fc31ebf4000,
title = "Transglutaminases: The missing link in nephrogenic systemic fibrosis",
abstract = "Nephrogenic systemic fibrosis (NSF), also known as nephrogenic fibrosing dermopathy (NFD), occurs in renal failure patients after gadolinium contrast exposure. The fibrosis of the dermis and subcutaneous septae accompanies fibrosis of other organs, including the heart, liver, lungs, and muscle. The fibrotic skin demonstrates increased dermal collagen, fibroblasts, and mucin. The mechanism by which gadolinium is associated with fibrosis is not known.We tested the hypothesis that upregulation of transglutaminases contributes to the fibrosis seen in the organs, including skin, of renal failure patients exposed to gadolinium contrast.We performed immunohistochemical studies using antibodies to transglutaminase-2, factor XIIIa, transglutaminase isopeptide, and the histiocyte marker CD68 on five archived skin biopsies of NSF. The results indicate that the dermal fibroblasts and histiocytes of NSF express transglutaminase-2, CD68, factor XIIIa, and transglutaminase isopeptide, indicating increased expression and/or activation of transglutaminases in NSF. We recommend further research into the use of transglutaminase inhibitors in the treatment and prevention of NSF.",
keywords = "Gadolinium, Nephrogenic fibrosing dermopathy, Nephrogenic systemic fibrosis, Renal failure, Transglutaminase",
author = "Parsons, {Amy C.} and Gil Yosipovitch and Sheehan, {Daniel J.} and Sang{\"u}eza, {Omar P.} and Greenberg, {Charles S.} and Sane, {David C.}",
year = "2007",
month = "10",
day = "1",
doi = "10.1097/DAD.0b013e318156e43f",
language = "English (US)",
volume = "29",
pages = "433--436",
journal = "American Journal of Dermatopathology",
issn = "0193-1091",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Transglutaminases

T2 - The missing link in nephrogenic systemic fibrosis

AU - Parsons, Amy C.

AU - Yosipovitch, Gil

AU - Sheehan, Daniel J.

AU - Sangüeza, Omar P.

AU - Greenberg, Charles S.

AU - Sane, David C.

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Nephrogenic systemic fibrosis (NSF), also known as nephrogenic fibrosing dermopathy (NFD), occurs in renal failure patients after gadolinium contrast exposure. The fibrosis of the dermis and subcutaneous septae accompanies fibrosis of other organs, including the heart, liver, lungs, and muscle. The fibrotic skin demonstrates increased dermal collagen, fibroblasts, and mucin. The mechanism by which gadolinium is associated with fibrosis is not known.We tested the hypothesis that upregulation of transglutaminases contributes to the fibrosis seen in the organs, including skin, of renal failure patients exposed to gadolinium contrast.We performed immunohistochemical studies using antibodies to transglutaminase-2, factor XIIIa, transglutaminase isopeptide, and the histiocyte marker CD68 on five archived skin biopsies of NSF. The results indicate that the dermal fibroblasts and histiocytes of NSF express transglutaminase-2, CD68, factor XIIIa, and transglutaminase isopeptide, indicating increased expression and/or activation of transglutaminases in NSF. We recommend further research into the use of transglutaminase inhibitors in the treatment and prevention of NSF.

AB - Nephrogenic systemic fibrosis (NSF), also known as nephrogenic fibrosing dermopathy (NFD), occurs in renal failure patients after gadolinium contrast exposure. The fibrosis of the dermis and subcutaneous septae accompanies fibrosis of other organs, including the heart, liver, lungs, and muscle. The fibrotic skin demonstrates increased dermal collagen, fibroblasts, and mucin. The mechanism by which gadolinium is associated with fibrosis is not known.We tested the hypothesis that upregulation of transglutaminases contributes to the fibrosis seen in the organs, including skin, of renal failure patients exposed to gadolinium contrast.We performed immunohistochemical studies using antibodies to transglutaminase-2, factor XIIIa, transglutaminase isopeptide, and the histiocyte marker CD68 on five archived skin biopsies of NSF. The results indicate that the dermal fibroblasts and histiocytes of NSF express transglutaminase-2, CD68, factor XIIIa, and transglutaminase isopeptide, indicating increased expression and/or activation of transglutaminases in NSF. We recommend further research into the use of transglutaminase inhibitors in the treatment and prevention of NSF.

KW - Gadolinium

KW - Nephrogenic fibrosing dermopathy

KW - Nephrogenic systemic fibrosis

KW - Renal failure

KW - Transglutaminase

UR - http://www.scopus.com/inward/record.url?scp=34648821231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34648821231&partnerID=8YFLogxK

U2 - 10.1097/DAD.0b013e318156e43f

DO - 10.1097/DAD.0b013e318156e43f

M3 - Article

C2 - 17890909

AN - SCOPUS:34648821231

VL - 29

SP - 433

EP - 436

JO - American Journal of Dermatopathology

JF - American Journal of Dermatopathology

SN - 0193-1091

IS - 5

ER -